Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Prostate Cancer and Protein Kinase Inhibitors

Additional Information

Published Date Sep 12, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5387
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Prostate Cancer and Protein Kinase Inhibitors in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Prostate Cancer and Protein Kinase Inhibitors.

    To find out more about Triple Analysis: Lymphoma, Prostate Cancer and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Prostate Cancer and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part III: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part III: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

This Report Includes the Following Companies:
4SC
AB Science
Abbott
Abiogen
Acceleron Pharma
ACT Biotech
Active Biotech
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Alfa Wassermann
Alfacell
Allist Pharmaceuticals
Allos Therapeutics
Allostera
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Amphora
Anavex Life Sciences
AndroBioSys
Ansaris
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Aprea
Apricus Biosciences
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Benitec
Berkeley Lab
Bio-Path Holdings
BioAxone
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biolex
BioLineRx
BioMarin
BioNetWorks
Bionovo
BioSante
Biostar
Biotecnol
Biotica Technology
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
Camurus
CanBas
Cancer Research Technology
Catalyst Biosciences
Cel-Sci
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Celltrion
Celsion
Center of Molecular Immunology
Cephalon
CerRx
Chemokine Therapeutics
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinical Data
Colby
CompleGen
Compugen
CoNCERT Pharmaceuticals
Cornerstone Pharmaceuticals
Cosmo Bioscience
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokine PharmaSciences
Cytokinetics
Cytopia
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dongkook Pharm
Dr Reddy’s
Dyax
Dynavax Technologies
ECI
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
Ensemble Discovery
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Favrille
Ferring
Forma Therapeutics
Formula Pharmaceuticals
Galapagos
Galena Biopharma
Gemin X Biotechnologies
Gemin X Pharmaceuticals
Genencor
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
GenPat77
Genta
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Got-a-Gene
GP Pharm
GPC Biotech
Green Cross
GTx
Hanmi
Harbor BioSciences
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hy BioPharma
Hypha Discovery
Idera Pharmaceuticals
IGF Oncology
ImClone Systems
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
ImmuPharma
Incozen Therapeutics
Incyte Corporation
Inex
Infinity Pharmaceuticals
Inhibiton Therapeutics
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intellikine
Intracel
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Ivy Medical Chemicals
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
KaloBios
Kalypsys
Karo Bio
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
Kissei
KuDOS
Kyowa Hakko Kirin
Leo
Lexicon Pharmaceuticals
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
Marina Biotech
MaxoCore Pharmaceuticals
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mojave Therapeutics
Molecular Insight
Molecular LogiX
Myrexis
Nano Terra
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novogen
Noxxon
Nycomed Pharma
Oasmia
Oncalis
OncoGenex Pharmaceuticals
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Orion Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Paladin Labs
Pantarhei Bioscience
Pathway Therapeutics
Pepscan Therapeutics
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Plexxikon
Portola Pharmaceuticals
Proacta
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Provid
Q Chip
QLT
Quantum Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Salzburg Therapeutics
Samtheo Biopharma
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sapphire Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
Seattle Genetics
SeleXel
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
Serometrix
SGX Pharmaceuticals
Shire
Siena Biotech
Silence Therapeutics
Soligenix
Sophiris Bio
SRI International
Sunesis
SuperGen
SuppreMol
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Synageva BioPharma
Synta Pharmaceuticals
Taiho
Takeda
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Tau Therapeutics
TauTaTis
TCD Pharma
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tokai Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TransTech Pharma
Trion Pharma
Twinstrand Therapeutics
UCB
Unigene
United Biomedical
Vaccinex
VasGene Therapeutics
Vaxon Biotech
Velacor Therapeutics
VentiRx Pharmaceuticals
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viralytics
ViroMed
ViroTarg
VM Discovery
Wyeth
XBiotech
Xcovery
Xencor
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zenotech
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abarelix
abiraterone acetate
AC-480
adecatumumab
aderbasib
AE-37
AEZS-108
AF-802
afatinib
aflibercept
alemtuzumab
ALT-801
alvocidib
AMG-386
amonafide dihydrochloride
amonafide malate
amrubicin hydrochloride
Angiozyme
apatinib
APC-100
APR-246
AR-42
ARC-100
ARQ-197
AT-7519
AT-9283
atrasentan
AVX-701
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
belinostat
bevacizumab
bexarotene
BEZ-235
BGT-226
BI-811283
BIBF-1120
bicalutamide
BMS-690514
BMS-754807
BMS-777607
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
brentuximab vedotin
brivanib alaninate
buserelin
Cabozantinib
CAL-101
carlumab
CBP-501
CC-223
cediranib
celecoxib
cetuximab
cixutumumab
cladribine
crizotinib
custirsen
dacomitinib
danusertib
dasatinib
DCVax-prostate
degarelix
denileukin diftitox
denosumab
deslorelin
DI-17E6
dinaciclib
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
elliptinium acetate
endoxifen
ENMD-2076
entinostat
enzastaurin hydrochloride
epirubicin
erlotinib
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
figitumumab
flutamide
foretinib
fostamatinib disodium
fulvestrant
galiximab
gataparsen
GDC-0980
gefitinib
goserelin
GSK-2118436
GTx-758
GVAX
GVX-3322
GX-301
HBP-347
HE-3235
histrelin
ibritumomab tiuxetan
IC-83
icrucumab
idronoxil
imatinib mesilate
INCB-028060
inecalcitol
inotuzumab ozogamicin
INSM-18
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interleukins
intetumumab
ipilimumab
irinotecan hydrochloride
irosustat
ispinesib mesylate
JI-101
KD032
KX2-391
lapatinib ditosylate
lenvatinib
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
linifanib
linsitinib
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
LY-2090314
LY-2275796
masitinib
MCS-110
MDV-3100
MGCD-265
midostaurin
mitoxantrone
MK-1775
MKC-1
MLN-8237
MM-111
motesanib diphosphate
MVA-BN Her-2 vaccine
Nab-docetaxel
nadroparin
neratinib
nilotinib
nilutamide
nimotuzumab
NPB-001-056
obinutuzumab
oblimersen sodium
ofatumumab
OGX-427
olaparib
olaratumab
ON-01910
onartuzumab
orteronel
OSI-027
OTS-102
ozarelix
P276-00
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
pazopanib hydrochloride
PD-0332991
pegdinetanib
perifosine
pertuzumab
PHA-848125AC
pixantrone
plitidepsin
PLX-3397
ponatinib
pralatrexate
ProstAtak
PROSTVAC
PRX-302
PX-866
quarfloxacin
quinacrine
quizartinib dihydrochloride
R-(-)-gossypol
RAF-265
ramucirumab
razoxane
Reditux
regorafenib
retaspimycin
rhIFN-alpha
ridaforolimus
rilotumumab
rituximab
romidepsin
ruxolitinib
RX-0201-N
sagopilone
sargramostim
SB-939
SCH-900776
seliciclib
siltuximab
sipuleucel-T
sirolimus
sobuzoxane
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
TAK-448
talmapimod
tandutinib
tasquinimod
telatinib
temsirolimus
Tenarad
teniposide
terameprocol
tivozanib
TOK-001
toremifene citrate
TRC-105
tremelimumab
triciribine phosphate
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
varlitinib
vemurafenib
volasertib
vosaroxin
XL-147
XL-281
XL-413
XL-647
XL-765
YM-155
zanolimumab
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Prostate Cancer and Protein Kinase Inhibitors.
    To find out more about Triple Analysis: Lymphoma, Prostate Cancer and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Prostate Cancer and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Leukemia, Lung Cancer and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Leukemia, Lung Cancer and Prostate Cancer. Learn More

Other selected research from the 'Oncology' category:


The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new protein kinase inhibitor drugs in oncology. Learn More


Triple Analysis: Breast Cancer, Prostate Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Learn More